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Abstract 
Background: Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. Recently, 
new oral anticoagulants have been introduced as alternatives to warfarin and acenocoumarol. In Europe, the Euro-
pean Medicines Agency has approved dabigatran, rivaroxaban and apixaban. Their advantages include: predictable 
pharmacokinetics, drug interactions and limited food, rapid onset of action and short half-life. However, they lack 
a specific reversal agent.
Material and Methods: A literature search was conducted through November 2015 for publications in the ISI Web 
of Knowledge, PubMed, Scopus and Cochrane Library using the keywords “apixaban”, “rivaroxaban”, “dabiga-
tran”, “new oral anticoagulants”, “dental treatment” and “dental implications”. We included studies published in 
English and Spanish over the last 10 years.
Results: Apixaban has been recently introduced in the daily medical practices for the control of thromboembolism. 
The number of patients taking apixaban is increasing. Management of patients on anticoagulation therapy requires 
that dentists can accurately assess the patient prior to dental treatments. It is important for dentists to have a sound 
understanding of the mechanisms of action and management guidelines for patients taking new oral anticoagu-
lants.
Conclusions: The dentist should consider carefully the management of patients on apixaban. This paper sets out a 
clinical guidance of dental practitioners treating these patients. There is a need for further clinical studies in order 
to establish more evidence-based guidelines for dental patients requiring apixaban.
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Introduction
In daily dental practice it is common to treat the patients 
being intervened with oral anticoagulants in order to 
prevent or treat thromboses. Patients receiving oral an-
ticoagulants have a greater risk of haemorrhage during 
odontological treatments.
Classically, they were treated exclusively with dicumari-
nic anticoagulant agents, among which are warfarin and 
acenocumarol (1), but the disadvantages of these anti-
coagulants is that their dose must be adjusted specifica-
lly for each patient; they interact with many other drugs 
and with certain foods, and their use requires periodic 
monitoring using the International Normalized Ratio 
(INR) (2).
Current research in the field of antithrombotic agents 
focuses on seeking the ideal oral anticoagulant that 
Article Number: 53004                http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System
Curto A, Albaladejo A. Implications of apixaban for dental treatments. J 
Clin Exp Dent. 2016;8(5):e611-4.
http://www.medicinaoral.com/odo/volumenes/v8i5/jcedv8i5p611.pdf
J Clin Exp Dent. 2016;8(5):e611-4.                                                                                                                                                                                     Dental management of apixaban
e612
will overcome some of the pitfalls of classic oral drugs. 
Thus, in recent years new anticoagulant agents have 
appeared, among which are apixaban, rivaroxaban and 
dabigatran. These new generation drugs do not require 
periodic laboratory-supervised monitoring and interact 
less with other drugs and foods (3,4). However, their use 
in comparison with traditional oral anticoagulants invol-
ves economic costs (5,6).
On 20 September 2012 The European Medicines Agen-
cy (EMA) authorized the use of apixaban for the pre-
vention of ictus and systemic clots in adult patients with 
non-valvular atrial fibrillation who had one or more of 
the following risk factors: ictus or transient ischaemic 
attack, an age of 75 or above, arterial hypertension, dia-
betes mellitus and symptomatic cardiac insufficiency 
equal to or greater than class 2 on the New York Heart 
Association (NYHA) scale (7). The commercial name of 
apixaban is Eliquis®.
Apixaban acts by inhibiting the coagulation factor Xa, 
indirectly inhibiting the platelet aggregation induced 
by thrombin. It prevents the formation of thrombin and 
hence clot formation. In comparison with classic dicu-
marinic anticoagulants, it inhibits vitamin K-dependent 
coagulation factors.
The drug is absorbed rapidly and its maximum concen-
trations are reached at 3-4 hours after administration. Its 
binding to human plasma proteins is approximately 8% 
and it has a half-life of 8-15 hours. It is mainly metabo-
lized by cytochrome CYP3A4/5; approximately 25% of 
the drug is eliminated by the kidney and 27% in urine. 
The plasma levels of the drug mainly depend on the dose 
administered and little variation is observed between in-
dividuals (8,9).
Currently, there is no antidote to haemorrhages induced 
by apixaban administration (10). Protamine, vitamin K 
or plasma transfusions do not affect its anticoagulant 
effect (11,12).
Material and Methods
In the present contribution we offer an exhaustive re-
view of the literature found in the ISI Web of Knowled-
ge, PubMed, Scopus and Cochrane Library in November 
2015, including articles published in the last 10 years in 
English and Spanish. The words used were “apixaban”, 
“rivaroxaban”, “dabigatran”, “new oral anticoagulants”, 
“dental treatment” and “dental implications” with the 
“and” boolean operator. Metaanalyses, systematic re-
views, clinical trials and case-control studies were con-
sidered. Specialized textbooks were also consulted.
Results
Laboratory tests are available that allow the plasma le-
vels of apixaban to be determined but they are not in wide 
use and are expensive. Currently, there is no scientific 
evidence to be able to establish a relationship between 
the duration of laboratory tests and the likelihood of 
the occurrence of haemorrhages in patients undergoing 
treatment with apixaban (13). Among the tests whose 
results may be altered by apixaban are chromogenic as-
says to assess anti-factor Xa activity, the prothrombin 
time and the activated partial thromboplastin time.
-Chromogenic assays to assess anti-factor Xa activity: 
Anti-factor Xa activity is directly related to the plasma 
concentration of apixaban. Maximum values are reached 
with the maximum plasma concentrations of the anticoa-
gulant (14,15).
-Prothrombin time: An increase is seen in the prothrom-
bin time, depending on the plasma concentration in the 
patients taking apixaban. This increase in the prothrom-
bin time has minimal effects (16).
-Activated partial thromboplastin time: The increase in 
the activated partial thromboplastin time is insignificant. 
Like the prothrombin time, this time is not suitable for 
measuring the effect of apixaban (17-20).
Certain dental treatments that involve a risk of haemo-
rrhage may require temporal interruption of apixaban 
administration. It is thus of great importance to plan in-
vasive dental treatments entailing a risk of haemorrhage 
ahead. When dealing with a patient receiving oral anti-
coagulants, it is necessary to judge the risk of haemorr-
hage in the dental procedure and the risk of thrombosis 
arising from the patient’s underlying pathology.
The risk of thrombosis in a patient is gauged by the at-
tendant physician and there are several factors that may 
govern such risk.
The suspension or not of apixaban and the actual mo-
ment of withdrawal depend on the risk of haemorrhage 
involved in the intervention. It is crucial to know the re-
nal status of the patient to evaluate the moment when the 
drug is to be suspended (21). The specialist physician 
will make the decision about whether the drug should be 
withdrawn or not (22).
In comparison with the new oral anticoagulants, tradi-
tional drugs have aroused considerable controversy re-
garding suspension of the anticoagulant prior to dental 
procedures (23).
Depending on the risk of haemorrhage of the dental pro-
cedure it is possible to classify dental treatments in two 
groups: procedures with a low risk of haemorrhage and 
procedures with medium and high risks of haemorrhage.
-Invasive procedures with a low risk of haemorrha-
ge: Considering the low risk of haemorrhage and the 
half-life of the drug it is not necessary to withdraw 
treatment with apixaban, with the exception of the dose 
scheduled for the day on which the dental treatment is 
to be carried out. The procedure should be performed 
12 hours after the last administration of apixaban or at 
24 hours if a dose is missed. Low-risk procedures in-
clude simple tooth extractions, oral surgery lasting less 
than 45 minutes and mucogingival surgical procedures 
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(if the haemorrhage is not very extensive). Before per-
forming an invasive procedure, if there has been a pre-
vious process of inflammation the risk of haemorrhage 
will be greater. 
Most dental interventions are considered invasive but 
with a low risk of haemorrhage, such that the suppres-
sion of apixaban prior to dental treatment is not neces-
sary. However, to date there are no scientific studies that 
support such an assertion owing to the short time that 
this anticoagulant has been available (24).
-Invasive procedures with a medium and high risk of 
haemorrhage: Within this group, treatment with apixa-
ban must always be withdrawn. The drug should be 
suspended at least 24 hours previously in the case of 
medium risk and at least 48 hours in cases of high risk. 
Owing to the short withdrawal time, no replacement 
therapy with low molecular weight heparin is neces-
sary. If the period of drug suspension is prolonged, the 
administration of low-molecular weight heparin is re-
commended (24-26).
In invasive dental procedures with a low risk of haemo-
rrhage and a medium or high risk if the patient has an 
altered kidney function, the time of apixaban suspension 
should be extended (Table 1). The extraction of more 
than three teeth at once is considered a medium-high 
risk procedure, as is the case of oral surgical procedu-
res lasting more than 45 minutes (23-27). In this group, 
the specialist physician must counsel the withdrawal of 
apixaban administration.
Both in procedures with a low risk of haemorrhage and 
Renal function (Clcr in ml/min) Low risk of haemorrhage Medium and high risk of haemorrhage
>50 24 hours before 48 hours before
30 - 50 48 hours before 72 -96 hours before
Table 1. Guide to the suppression of apixaban.
Low risk of haemorrhage Medium and high risk of haemorrhage
The usual dose is administered on the day after the 
intervention
Administration is reinstated  when a satisfactory degree 
of haemostasis has been reached
Table 2. Guide to the reinstatement of treatment with apixaban.
in those with a medium or high risk, local haemostatic 
measures must be taken (28-33).
Once the dental intervention has been completed, the 
time when apixaban treatment should be reinstated is 
determined by the risk of haemorrhage involved in the 
invasive procedure performed (Table 2) (30-33).
Conclusions
Patients undergoing treatment with oral anticoagulants 
have a greater risk of haemorrhaging when receiving in-
vasive dental treatments.
In view of the drawbacks of the classic dicumarinic an-
ticoagulants detected in recent years, new oral anticoa-
gulants have been developed, among which is apixaban. 
The advantages of these new anticoagulants are as fo-
llows: they have predictable pharmacokinetics, they ex-
hibit fewer interactions with drugs and foods, no perio-
dic analytical controls are required and their half-life is 
shorter. The main drawback is the absence of an efficient 
antidote if haemorrhages appear.
Clinical experience with the new anticoagulants in den-
tistry is very limited, but it is to be expected that treatment 
with these new oral drugs will increase in the future. As 
health professionals we must be aware of the existence 
of these new oral anticoagulants and must be ready to re-
port the possible appearance of secondary effects to the 
pertinent authorities. Finally, protocols must be develo-
ped based on the scientific evidence in order to know 
how these patients should be handled from the point of 
view of dental interventions.
References
1. Mingarro-de-León A, Chaveli-López B. Alternative to oral di-
coumarin anticoagulants: Considerations in dental care. J Clin Exp 
Dent. 2013;5:e273-8.
2. Bashir MA, Ray R, Sarda P, Li S, Corbett S. Determination of a safe 
INR for joint injections in patients taking warfarin. Ann R Coll Surg 
Engl. 2015;97:589-91.
3. Rillig A, Lin T, Plesman J, Heeger CH, Lemes C, Metzner A, et al. 
Apixaban, Rivaroxaban and Dabigatran in Patients undergoing Atrial 
Fibrillation Ablation. J Cardiovasc Electrophysiol. 2015 Oct 14. 
4. Imberti D, Gallerani M, Manfredini R. Therapeutic potential of 
apixaban in the prevention of venous thromboembolism in patients 
undergoing total knee replacement surgery. J Thromb Thrombolysis. 
2012;34:208-13.
5. Barón Esquivias G, Escolar Albaladejo G, Zamorano JL, Betegón 
Nicolás L, Canal Fontcuberta C, de Salas-Cansado M, et al. Cost-
effectiveness Analysis Comparing Apixaban and Acenocoumarol in 
the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrilla-
tion in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:680-90.
6. Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-
Zaleski I. Stroke prevention in patients with atrial fibrillation in Fran-
ce: comparative cost-effectiveness of new oral anticoagulants (apixa-
ban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 
2014;17:587-98.
7. Budovich A, Zargarova O, Nogid A. Role of Apixaban (Eliquis) in 
the Treatment And Prevention of Thromboembolic Disease. Pharm 
Ther. 2013;38:206-31.
8. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA. Safety, 
pharmacokinetics and pharmacodynamics of multiple oral doses of 
apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharma-
col. 2013;76:776-86. 
9. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia 
J Clin Exp Dent. 2016;8(5):e611-4.                                                                                                                                                                                     Dental management of apixaban
e614
R. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, 
pharmacokinetics, pharmacodynamics and food effect in healthy sub-
jects. Br J Clin Pharmacol. 2013;75:476-87.
10. Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, et 
al. Recommendations for the emergency management of complications 
associated with the new direct oral anticoagulants (DOACs), apixaban, 
dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399-412.
11. Connors JM. Antidote for Factor Xa Anticoagulants. N Engl J 
Med. 2015;25:2471-2.
12. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, 
Reverter JC, Sanz VV. Reversal of Apixaban Induced Alterations in 
Hemostasis by Different Coagulation Factor Concentrates: Signifi-
cance of Studies In Vitro with Circulating Human Blood. PloS one. 
2013;8:e78696.
13. Kanemoto M, Ikeda Y, Fujii T. How to Avoid Adverse Events 
During Apixaban Therapy in Patients With Atrial Fibrillation. Circ J. 
2015;12:2539-40.
14. Osanai H, Ajioka M, Masutomi T, Kuwayama T, Ishihama S, Sakama-
to Y, et al. Measurement of Anti-Factor Xa Activity in Patients on Apixa-
ban for Non-Valvular Atrial Fibrillation. Circ J. 2015;12:2584-90.
15. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et 
al. Chromogenic laboratory assays to measure the factor Xa-inhibiting 
properties of apixaban--an oral, direct and selective factor Xa inhibi-
tor. J Thromb Thrombolysis. 2011;32:183-7.
16. Kanemoto M, Kuhara H, Ueda T, Shinohara T, Oda T, Nakao F, et 
al. Association of apixaban therapy and prothrombin time in patients 
with atrial fibrillation. Circ J. 2014;78:2651-6.
17. Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Co-
ppens M. In vivo increase in thrombin generation by four-factor pro-
thrombin complex concentrate in apixaban-treated healthy volunteers. 
J Thromb Haemost. 2015;13:1799-805.
18. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the 
direct oral anticoagulants. Br J Haematol. 2016;172:315-36.
19. Cuker A, Husseinzadeh H. Laboratory measurement of the anti-
coagulant activity of edoxaban: a systematic review. J Thromb Throm-
bolysis. 2015;39:288-94.
20. Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom 
JW. Comparison of the effects of apixaban and rivaroxaban on pro-
thrombin and activated partial thromboplastin times using various rea-
gents. J Thromb Haemost. 2014;12:1810-5.
21. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feu-
ring M. Dabigatran etexilate--a novel, reversible, oral direct thrombin 
inhibitor: interpretation of coagulation assays and reversal of anticoa-
gulant activity. Thromb Haemost. 2010;103:1116-27.
22. Martínez-López F, Oñate-Sánchez R, Arrieta-Blanco JJ, Oñate-Ca-
brerizo D, Cabrerizo-Merino MD. Clinical diseases with thrombotic 
risk and their pharmacologycal treatment: how they change the the-
rapeutic attitude in dental treatments. Med Oral Patol Oral Cir Bucal. 
2013;18:e888-95.
23. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients 
undergoing an elective pro-cedure or surgery. Blood. 2012;120:2954-
62.
24. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral 
anticoagulants and their implications for the management of dental pa-
tients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-
41.
25. Schulman S, Crowther MA. How I treat anticoagulants in 2012: 
new and old anticoagulants, and when and how to switch. Blood. 
2012;119:3016-23.
26. Little JW. New oral anticoagulants: will they replace warfarin? 
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575-80.
27. Cardona-Tortajada F, Sainz-Gómez E, Figuerido-Garmendia J, de 
Robles-Adsuar AL, Morte-Casabó A, Giner-Muñoz F, et al. Dental ex-
tractions in patients on antiplatelet therapy. A study conducted by the 
Oral Health Department of the Navarre Health Service (Spain). Med 
Oral Patol Oral Cir Bucal. 2009;14:e588-92. 
28. Faraoni D, Samama CM, Ranucci M, Dietrich W, Levy JH. Perio-
perative management of patients receiving new oral anticoagulants: an 
international survey. Clin Lab Med. 2014;34:637-54.
29. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of 
acute stroke in patients taking novel oral anticoagulants. Int J Stroke. 
2014;9:627-32.
30. Lai A, Davidson N, Galloway SW, Thachil J. Perioperati-
ve management of patients on new oral anticoagulants. Br J Surg. 
2014;101:742-9.
31. Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier 
F. Management of non-vitamin K antagonist oral anticoagulants in the 
perioperative setting. Biomed Res Int. 2014;2014:385014.
32. Baron TH, Kamath PS, McBane RD. Management of antithrombo-
tic therapy in patients undergoing invasive procedures. N Engl J Med. 
2013;368:2113-24.
33. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et 
al. Surgery and invasive procedures in patients on long-term treatment 
with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Re-
commendations of the Working Group on Perioperative Haemostasis 
and the French Study Group on Thrombosis and Haemostasis. Arch 
Cardiovasc Dis. 2011;104:669-76.
Conflict of Interest
The authors declare that there is no conflict of interests regarding the 
publication of this paper.
